Saccharomyces boulardii para Antibiotic-Associated Diarrhea (AAD)
A Evidências Vários grandes ensaios clínicos mostram de forma consistente benefícios significativos.Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
Conclusão
Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.
Key Study Findings
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
vs: None
Outcome: Probiotic prescribing habits of Italian PCPs
Efeito: L. rhamnosus GG used by 91.8%
None
População: Italian primary care pediatricians
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
Efeito: None
None
População: Pediatric population
Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None
vs: None
Outcome: None
Efeito: None
None
População: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
vs: None
Outcome: Clinical guideline recommendations for pediatric GI
Efeito: None
None
População: Pediatric patients with GI disorders
Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None
vs: None
Outcome: C. difficile infection treatment outcomes
Efeito: None
None
População: Patients with C. difficile infection
Randomized Controlled Trial
n=47
1 weeks
[A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants …
Dose: None
vs: Control
Outcome: Gut microbiota composition
Efeito: None
P<0.017
População: Children
Key Statistics
25
Estudos
5000
Participantes
↑
Positive
A
Nota
Referenced Papers
Probiotics and antimicrobial …
2025
26 citações
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 citações
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Open forum infectious …
2024
7 citações
Zhongguo dang dai …
2024
5 citações
Advances in experimental …
2024
2 citações
Therapeutic advances in …
2023
97 citações
Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children.
Systematic Review
Frontiers in pharmacology
2023
20 citações
Cureus
2023
19 citações
Cureus
2023
5 citações
The Journal of …
2023
1 citações
Archivos argentinos de …
2022
23 citações
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.
Review
World journal of …
2019
92 citações
Advances in experimental …
2019
17 citações
Frontiers in medicine
2018
450 citações
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
Systematic Review
PloS one
2018
205 citações
Pharmacological research
2018
132 citações
World journal of …
2018
52 citações
The American journal …
2018
46 citações
World journal of …
2017
68 citações
Journal of pediatric …
2016
233 citações
Clinical and experimental …
2016
82 citações
Open forum infectious …
2016
58 citações
Digestive diseases (Basel, …
2016
37 citações
The Cochrane database …
2015
233 citações
Antibiotics (Basel, Switzerland)
2015
104 citações
Journal of clinical …
2015
35 citações
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 citações
Nutricion hospitalaria
2015
5 citações
Expert opinion on …
2014
57 citações
MMW Fortschritte der …
2014
14 citações
MMW Fortschritte der …
2014
3 citações
The American journal …
2012
104 citações
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use.
Other
The American journal …
2012
5 citações
Medycyna wieku rozwojowego
2012
1 citações
Journal of clinical …
2011
432 citações
World journal of …
2010
512 citações
Journal for specialists …
2010
22 citações
Probiotics.
Review
American journal of …
2010
European journal of …
2009
91 citações
Current opinion in …
2009
82 citações
Advances in biochemical …
2008
535 citações
Journal of clinical …
2008
Probiotics.
Review
American family physician
2008
The Journal of …
2007
265 citações
The Cochrane database …
2007
The American journal …
2006
918 citações
Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials.
Meta-Analysis
CMAJ : Canadian …
2006
197 citações
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 citações
Medical science monitor …
2006
The American journal …
2001
648 citações
International journal of …
2000
181 citações
Clinical infectious diseases …
1998
346 citações
Anaerobe
1997
40 citações
Gastroenterology
1989
418 citações
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosagens Comumente Utilizadas
- general:
- 250-500 mg/day (equivalent to 5-10 billion CFU)
- aadprevention:
- 500 mg/day (start with antibiotic, continue 7 days after)
- cdiffprevention:
- 500 mg twice daily as adjunct to standard therapy
- travelersdiarrhea:
- 250-500 mg/day starting 5 days before travel
Limite superior: Well-tolerated up to 1,000 mg/day in clinical trials
Dosagens Estudadas em Pesquisas
| Dosagem | Duração | Efeito | N |
|---|---|---|---|
| None | -- | Mixed | 279 |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | 1 weeks | Positive | 47 |
| None | 20 weeks | Positive | 564 |
| None | -- | Positive | -- |
Melhor horário: Can be taken with or without food; space 2 hours from antifungals
Safety & Side Effects
Efeitos Colaterais Relatados
- ⚠ Mild gas and bloating
- ⚠ Rare: fungemia in critically ill patients with central venous catheters
- ⚠ Thirst (yeast may increase water requirements)
- ⚠ Very rare: potential environmental contamination risk in ICU settings
Interações Conhecidas
- ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
- ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
- ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)
Ingestão máxima tolerável: Well-tolerated up to 1,000 mg/day in clinical trials
Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.
Frequently Asked Questions
Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.
Related Evidence
Outros ingredientes para Antibiotic-Associated Diarrhea (AAD)
Saccharomyces boulardii para outras condições
References
- [1] Ailim Margarita Carías Domínguez et al.. Probiotics Antimicrob Proteins. 2025. Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review. doi:10.1007/s12602-024-10353-w PubMed
- [2] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
- [3] Giacomo Biasucci et al.. Antibiotics (Basel). 2025. Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. doi:10.3390/antibiotics14060577 PubMed
- [4] Sylvia Cruchet et al.. Bol Med Hosp Infant Mex. 2025. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. doi:10.24875/BMHIM.M25000043 PubMed
- [5] Vladimir Hodzhev et al.. Open Forum Infect Dis. 2024. High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Adults: A … doi:10.1093/ofid/ofae615 PubMed
- [6] Su-Wei Zhang et al.. Zhongguo Dang Dai Er Ke Za Zhi. 2024. [A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants and young children]. doi:10.7499/j.issn.1008-8830.2401129 PubMed
- [7] Elvira Ingrid Levy et al.. Adv Exp Med Biol. 2024. Clostridioides difficile Infections: Prevention and Treatment Strategies. doi:10.1007/978-3-031-58572-2_11 PubMed
- [8] Dhanasekhar Kesavelu et al.. Ther Adv Infect Dis. 2023. Current understanding of antibiotic-associated dysbiosis and approaches for its management. doi:10.1177/20499361231154443 PubMed
- [9] Qingrui Yang et al.. Front Pharmacol. 2023. Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children. doi:10.3389/fphar.2023.1153070 PubMed
- [10] Sarath Gopalan et al.. Cureus. 2023. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. doi:10.7759/cureus.46314 PubMed
- [11] Nyier W Doar et al.. Cureus. 2023. Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. doi:10.7759/cureus.40261 PubMed
- [12] Amarender S Puri. J Assoc Physicians India. 2023. The Role of Yeast Probiotics in Gastrointestinal Conditions: An Overview. doi:10.5005/japi-11001-0235 PubMed
- [13] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
- [14] Dorota Czerucka et al.. World J Gastroenterol. 2019. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. doi:10.3748/wjg.v25.i18.2188 PubMed
- [15] Meltem Dinleyici et al.. Adv Exp Med Biol. 2019. Clostridium difficile Colitis Prevention and Treatment. doi:10.1007/5584_2018_322 PubMed
- [16] Lynne V McFarland et al.. Front Med (Lausanne). 2018. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. doi:10.3389/fmed.2018.00124 PubMed
- [17] Jason C Sniffen et al.. PLoS One. 2018. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. doi:10.1371/journal.pone.0209205 PubMed
- [18] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
- [19] Jie Chen et al.. World J Pediatr. 2018. Chinese clinical practice guidelines for acute infectious diarrhea in children. doi:10.1007/s12519-018-0190-2 PubMed
- [20] Ronald L Koretz. Am J Gastroenterol. 2018. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? doi:10.1038/s41395-018-0138-0 PubMed
- [21] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
- [22] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
- [23] Heike Stier et al.. Clin Exp Gastroenterol. 2016. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. doi:10.2147/CEG.S111003 PubMed
- [24] Stephan Ehrhardt et al.. Open Forum Infect Dis. 2016. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. doi:10.1093/ofid/ofw011 PubMed
- [25] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
- [26] Joshua Z Goldenberg et al.. Cochrane Database Syst Rev. 2015. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub4 PubMed
- [27] Lynne V McFarland. Antibiotics (Basel). 2015. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. doi:10.3390/antibiotics4020160 PubMed
- [28] Alfredo Guarino et al.. J Clin Gastroenterol. 2015. Probiotics for Prevention and Treatment of Diarrhea. doi:10.1097/MCG.0000000000000349 PubMed
- [29] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
- [30] Carlos Pérez. Nutr Hosp. 2015. [Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. doi:10.3305/nh.2015.31.sup1.8709 PubMed
- [31] Ener Cagri Dinleyici et al.. Expert Opin Biol Ther. 2014. Saccharomyces boulardii CNCM I-745 in different clinical conditions. doi:10.1517/14712598.2014.937419 PubMed
- [32] George Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
- [33] G Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
- [34] Pietro Pozzoni et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. doi:10.1038/ajg.2012.56 PubMed
- [35] Maria Assunta Zocco et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. doi:10.1038/ajg.2012.222 PubMed
- [36] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed
- [37] Stefano Guandalini. J Clin Gastroenterol. 2011. Probiotics for prevention and treatment of diarrhea. doi:10.1097/MCG.0b013e3182257e98 PubMed
- [38] Lynne V McFarland. World J Gastroenterol. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. doi:10.3748/wjg.v16.i18.2202 PubMed
- [39] Kathleen Jones. J Spec Pediatr Nurs. 2010. Probiotics: preventing antibiotic-associated diarrhea. doi:10.1111/j.1744-6155.2010.00231.x PubMed
- [40] Nancy Toedter Williams. Am J Health Syst Pharm. 2010. Probiotics. doi:10.2146/ajhp090168 PubMed
- [41] Yvan Vandenplas et al.. Eur J Pediatr. 2009. Saccharomyces boulardii in childhood. doi:10.1007/s00431-008-0879-7 PubMed
- [42] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
- [43] Michael de Vrese et al.. Adv Biochem Eng Biotechnol. 2008. Probiotics, prebiotics, and synbiotics. doi:10.1007/10_2008_097 PubMed
- [44] Shira Idit Doron et al.. J Clin Gastroenterol. 2008. Probiotics for prevention of antibiotic-associated diarrhea. doi:10.1097/MCG.0b013e3181618ab7 PubMed
- [45] Benjamin Kligler et al.. Am Fam Physician. 2008. Probiotics. PubMed
- [46] Michael de Vrese et al.. J Nutr. 2007. Probiotics and prebiotics: effects on diarrhea. doi:10.1093/jn/137.3.803S PubMed
- [47] B C Johnston et al.. Cochrane Database Syst Rev. 2007. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub2 PubMed
- [48] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
- [49] Bradley C Johnston et al.. CMAJ. 2006. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. doi:10.1503/cmaj.051603 PubMed
- [50] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
- [51] Mehmet Can et al.. Med Sci Monit. 2006. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. PubMed
- [52] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
- [53] E Bergogne-Bérézin. Int J Antimicrob Agents. 2000. Treatment and prevention of antibiotic associated diarrhea. doi:10.1016/s0924-8579(00)00293-4 PubMed
- [54] C Högenauer et al.. Clin Infect Dis. 1998. Mechanisms and management of antibiotic-associated diarrhea. doi:10.1086/514958 PubMed
- [55] L V McFarland et al.. Anaerobe. 1997. Pharmaceutical probiotics for the treatment of anaerobic and other infections. doi:10.1006/anae.1996.0062 PubMed
- [56] C M Surawicz et al.. Gastroenterology. 1989. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. doi:10.1016/0016-5085(89)91613-2 PubMed
Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.